These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 20067460

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L, Cha C, Oshinsky G, Venkatraman E, Zelefsky M, Leibel S.
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [Abstract] [Full Text] [Related]

  • 4. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [Abstract] [Full Text] [Related]

  • 5. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    Joseph J, Al-Qaisieh B, Ash D, Bottomley D, Carey B.
    BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
    [Abstract] [Full Text] [Related]

  • 6. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS, Martinez AA, Horwitz EM, Gustafson GS, Gonzalez JA, Spencer WF, Brabbins DS, Dmuchowski CF, Hollander JB, Vicini FA.
    Cancer J Sci Am; 1997 Dec; 3(6):346-52. PubMed ID: 9403047
    [Abstract] [Full Text] [Related]

  • 7. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
    Khaksar SJ, Laing RW, Henderson A, Sooriakumaran P, Lovell D, Langley SE.
    BJU Int; 2006 Dec; 98(6):1210-5. PubMed ID: 17034501
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Henry AM, Al-Qaisieh B, Gould K, Bownes P, Smith J, Carey B, Bottomley D, Ash D.
    Int J Radiat Oncol Biol Phys; 2010 Jan 01; 76(1):50-6. PubMed ID: 20005453
    [Abstract] [Full Text] [Related]

  • 17. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
    Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2010 Aug 01; 77(5):1315-21. PubMed ID: 20044216
    [Abstract] [Full Text] [Related]

  • 18. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA, Kestin LL, Martinez AA.
    Tech Urol; 2000 Jun 01; 6(2):135-45. PubMed ID: 10798815
    [Abstract] [Full Text] [Related]

  • 19. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
    Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS.
    Cancer; 2000 Jul 01; 89(1):135-41. PubMed ID: 10897010
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.